Clinical trials: Endometrial
Ovary Cancer, Endometrial Cancer
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
The primary purpose of the study is to determine which of four components (symptom-burden tailored app, exercise partner, oncology provider engagement, coaching) added to a core intervention of a wearable activity tracker and…
- Conditions
- Ovary Cancer, Endometrial Cancer, Uterine Cancer, Cervical Cancer
- Trial name
- NCT05743517
- Testing
- Fit4Treatment
- Where
- United States
- Volunteers
- 192 people
- Sponsor
- Northwestern University
Solid Tumor, Metastatic Ovary Cancer
A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors
The goal of this clinical trial is to evaluate the safety and tolerability of TJ037130 in participants with advanced or metastatic solid tumors, and to determine the Potential Optimal Biological Dose (POBD) of TJ037130 for…
- Conditions
- Solid Tumor, Metastatic Ovary Cancer, Metastatic Gastric Cancer, Metastatic Endometrial Carcinoma
- Trial name
- NCT07715747
- Testing
- TJ037130
- Where
- China
- Volunteers
- 128 people
- Sponsor
- TJ Biopharma Co., Ltd.
Endometrial Carcinoma, Neoplasms, Endometrial
Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer
This is an open-label study, meaning both the researchers and participants will know which treatment is being given. The study has two parts. In Part 1, researchers will identify the most suitable SC dose.
- Trial name
- SAPPHIRE (NCT07860450)
- Testing
- Dostarlimab, Carboplatin and paclitaxel
- Volunteers
- 378 people
- Sponsor
- GlaxoSmithKline
Endometrial Cancer
Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
This is a single arm, Phase II study using the combination of atezolizumab and bevicacizumab in women with advanced, recurrent or persistent endometrial cancer.
- Trial name
- NCT03526432
- Testing
- Bevacizumab, Atezolizumab
- Where
- 3 sites in United States
- Volunteers
- 110 people
- Sponsor
- University of Oklahoma
Endometrial Adenocarcinoma, Endometrial Carcinosarcoma
Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
This study will compare the effects of treatment with nivolumab alone versus those of nivolumab plus the experimental drug BMS-986205.
- Trial name
- NCT04106414
- Testing
- Nivolumab, BMS- 986205
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Endometrial Cancer, Cancer of Endometrium
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
Background: Endometrial cancer (EC) of the uterus is becoming more common in the US. Sometimes EC often has increased levels of a protein called HER2. Cancers with HER2 tend to be more aggressive and have poorer outcomes.
- Conditions
- Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium, Endometrial Carcinoma
- Trial name
- NCT06253494
- Testing
- AdHER2DC vaccine, Pembrolizumab, N-803
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
The study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample.
- Trial name
- Fern-EC-01 (NCT06340568)
- Testing
- BNT323/DB-1303, Doxorubicin, Paclitaxel
- Where
- 206 sites in United States, Argentina and 25 more
- Volunteers
- 480 people
- Sponsor
- BioNTech SE
Solid Tumor, Advanced Solid Tumor
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
The goal of the Monotherapy Dose Escalation phase (Part 1) of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for…
- Conditions
- Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor
- Trial name
- NCT06586957
- Testing
- NKT3964, Paclitaxel, Doxorubicin
- Where
- 20 sites in United States, South Korea
- Volunteers
- 238 people
- Sponsor
- NiKang Therapeutics, Inc.
Endometrial Adenocarcinoma, Endometrial Cancer
QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
This is a prospective, single-arm, multicenter Phase II study evaluating the efficacy and safety of QL1706 combined with chemotherapy in patients with advanced recurrent or metastatic endometrial cancer who progressed after prior…
- Trial name
- QLPPEC/GOG-003 (NCT06917092)
- Testing
- QL1706 combined with chemotherapy ± Bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Endometrial Cancer
Study of EV for Recurrent Endometrial Carcinoma
This study is testing a drug called enfortumab vedotin in up to 12 patients with advanced endometrial (uterine) cancer that has worsened after previous treatments, including immunotherapy.
- Trial name
- EV-4-EC (NCT07139977)
- Testing
- Enfortumab Vedotin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- William Bradley
Postmenopausal Women, Intrauterine Diseases
Office Hysteroscopy in Postmenopausal Women: A Randomized Trial of Cervical Preparation Strategies
The goal of this randomized controlled trial is to evaluate the effectiveness of different cervical preparation strategies before office hysteroscopy in postmenopausal women undergoing evaluation for intrauterine pathology.
- Conditions
- Postmenopausal Women, Intrauterine Diseases, Endometrial Pathology, Postmenopausal Bleeding
- Trial name
- NCT07697781
- Testing
- No Cervical Preparation, Misoprostol ( Cytotec) 200 microgram a tablet, Vaginal Estrogen (7-Day Regimen)
- Where
- Tunisia
- Volunteers
- 120 people
- Sponsor
- Faculty of Medicine of Tunis
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
This clinical trial studies whether an intervention supported by technology (blended e-health intervention) works to improve fear of progression (FOP) in women with gynecologic or breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT07741968
- Testing
- Best Practice, Interview, Supportive Care
- Where
- 11 sites in United States
- Volunteers
- 126 people
- Sponsor
- City of Hope Medical Center
Endometrial Cancer
Effect of Weight Management on AMPK Activation in the Adjunctive Treatment of Endometrial Cancer
This study will randomly assign overweight or obese patients with endometrial cancer undergoing fertility-sparing treatment to two groups.
- Trial name
- NCT07879365
- Testing
- DEAR-Based Comprehensive Weight Management, Balanced Diet and Self-Directed Exercise
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Peking University People's Hospital
Endometrial Cancer
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
This study will test whether the combination of radiation and Dostarlimab is an effective treatment for women with MMR-D/MSI-H endometrial cancer who have recently undergone surgery.
- Trial name
- NCT04774419
- Testing
- Intensity modulated radiation therapy (IMRT), Dostarlimab, Hypofractionated IMRT
- Where
- 7 sites in United States
- Volunteers
- 62 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer, Endometrial Cancer
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
This is a data collection study, also referred to as a "screening" study; no investigational or standard therapy will be administered as part of this study.
- Conditions
- Ovarian Cancer, Endometrial Cancer, Colo-rectal Cancer, Cholangiocarcinoma
- Trial name
- NCT05124743
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Alaunos Therapeutics
Ovary Cancer, Endometrial Cancer
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
Endometrial cancer is the most common gynecologic cancer and ovarian cancer is the most lethal. The management of both advanced cancers is a combination of chemotherapy and surgery.
- Conditions
- Ovary Cancer, Endometrial Cancer, Uterine Cancer
- Trial name
- FAST (NCT05990426)
- Testing
- FAST Intervention
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Endometrial Cancer, Recurrent Endometrial Cancer
ALPINE: Maintenance Letrozole/Abemaciclib
The purpose of this research study is to see if the study drugs abemaciclib and letrozole are effective and safe for participants with estrogen-receptor positive (ER+), mismatch repair proficient, tumor protein p53 (TP53)…
- Conditions
- Endometrial Cancer, Recurrent Endometrial Cancer, TP53
- Trial name
- NCT06366347
- Testing
- Abemaciclib, Letrozole, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Solid Cancers
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are.
- Trial name
- NCT07186842
- Testing
- BNT329, CA19-9-targeting monoclonal antibody
- Where
- 18 sites in United States, Australia and 3 more
- Volunteers
- 245 people
- Sponsor
- BioNTech SE
KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors…
- Conditions
- KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
- Trial name
- NCT07458347
- Testing
- KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab
- Where
- 9 sites in United States
- Volunteers
- 545 people
- Sponsor
- Kestrel Therapeutics, Inc.